BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31792631)

  • 1. Early fibrosis regression by shear wave elastography after successful direct-acting anti-HCV therapy.
    Kohla MAS; Fayoumi AE; Akl M; Abdelkareem M; Elsakhawy M; Waheed S; Abozeid M
    Clin Exp Med; 2020 Feb; 20(1):143-148. PubMed ID: 31792631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
    Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
    J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant decrease in liver stiffness detected by two dimensional shear-wave elastography after treatment with direct-acting antiviral agents in patients with chronic Hepatitis C.
    Yaraş S; Sezgin O; Üçbilek E; Özdoğan O; Altıntaş E
    Turk J Gastroenterol; 2020 Feb; 31(2):142-147. PubMed ID: 32141823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Liver Stiffness and Noninvasive Fibrosis Scores in Egyptian Adolescents Successfully Treated with Ledipasvir-Sofosbuvir for Chronic Hepatitis C Virus Infection.
    Fahmy DM; Shokeir M; El Zeiny SM; Jonas MM; Abdallah A
    J Pediatr; 2021 Apr; 231():110-116. PubMed ID: 33347957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral.
    Li XH; Huang R; Yang M; Wang J; Gao YH; Jin Q; Ma DL; Wei L; Rao HY
    World J Gastroenterol; 2022 May; 28(20):2214-2226. PubMed ID: 35721884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients.
    Abdel Alem S; Elsharkawy A; El Akel W; Abdelaziz AO; Salama RM; El-Sayed MH; El Kassas M; Anees M; Shedeed M; Abdelsalam F; Ziada DH; El Shazly Y; El-Serafy M; Waked I; Esmat G; Doss W
    Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):1009-1016. PubMed ID: 31418303
    [No Abstract]   [Full Text] [Related]  

  • 7. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Tada T; Kumada T; Toyoda H; Mizuno K; Sone Y; Kataoka S; Hashinokuchi S
    J Gastroenterol Hepatol; 2017 Dec; 32(12):1982-1988. PubMed ID: 28299813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing significant fibrosis using imaging-based elastography in chronic hepatitis B patients: Pilot study.
    Park HS; Choe WH; Han HS; Yu MH; Kim YJ; Jung SI; Kim JH; Kwon SY
    World J Gastroenterol; 2019 Jul; 25(25):3256-3267. PubMed ID: 31333316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV.
    El-Garem H; AbdAllah M; Omar H; Cordie A; Abdel Alem S; Mohey Eldin Elzahry MA; Ghaith D; Abou El-Soud NH; Kamal W; Elsharkawy A; Esmat G
    Expert Rev Gastroenterol Hepatol; 2019 Jul; 13(7):693-698. PubMed ID: 31043104
    [No Abstract]   [Full Text] [Related]  

  • 10. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents.
    Hsu WF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen HY; Wang HW; Huang GT; Peng CY
    BMC Gastroenterol; 2019 Apr; 19(1):63. PubMed ID: 31029101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals.
    Mogahed EA; El-Karaksy H; Abdullatif H; Yasin NA; Nagy A; Alem SA; Eldeen HG; El-Raziky MS
    J Pediatr; 2021 Jun; 233():126-131. PubMed ID: 33577805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.
    Bachofner JA; Valli PV; Kröger A; Bergamin I; Künzler P; Baserga A; Braun D; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens JC
    Liver Int; 2017 Mar; 37(3):369-376. PubMed ID: 27678216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence.
    Korda D; Lenard ZM; Gerlei Z; Jakab Z; Haboub-Sandil A; Wagner L; Varga M; Cseprekal O; Marton A; Horvathy D; Takacs S; Doros A; Mathe Z
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):27-32. PubMed ID: 29049126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive Assessment of Fibrosis Regression after Direct-acting Antiviral Treatment in Hepatitis C Virus Patients.
    Davidov Y; Kleinbaum Y; Inbar Y; Cohen-Ezra O; Veitsman E; Weiss P; Likhter M; Berdichevski T; Katsherginsky S; Hassid A; Tsaraf K; Silverberg D; Ben Ari Z
    Isr Med Assoc J; 2021 Dec; 23(12):794-800. PubMed ID: 34954919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment.
    Niu B; Zang W; Zhou H; Mi Y; Lu C; Li P
    BMC Gastroenterol; 2023 Apr; 23(1):102. PubMed ID: 37013471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
    Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
    J Viral Hepat; 2021 Sep; 28(9):1284-1292. PubMed ID: 34105867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.
    Yosry A; Fouad R; Alem SA; Elsharkawy A; El-Sayed M; Asem N; Hassan E; Ismail A; Esmat G
    Arab J Gastroenterol; 2016 Jun; 17(2):78-83. PubMed ID: 27353055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
    Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
    World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry.
    Knop V; Mauss S; Goeser T; Geier A; Zimmermann T; Herzer K; Postel N; Friedrich-Rust M; Hofmann WP;
    J Viral Hepat; 2020 Jul; 27(7):690-698. PubMed ID: 32096310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.